Efficacy of neoadjuvant cisplatin in triple-negative breast cancer

Journal of Clinical Oncology

Volumn 28, Issue 7, 2010, Pages 1145-1153

  Silver, Daniel P ^a   Richardson, Andrea L ^a   Eklund, Aron C ^a   Wang, Zhigang C ^a   Szallasi, Zoltan ^a   Li, Qiyuan ^a   Juul, Nicolai ^a   Leong, Chee Onn ^a   Calogrias, Diana ^a   Buraimoh, Ayodele ^a   Fatima, Aquila ^a   Gelman, Rebecca S ^a   Ryan, Paula D ^a   Tung, Nadine M ^a   De Nicolo, Arcangela ^a   Ganesan, Shridar ^a   Miron, Alexander ^a   Colin, Christian ^a   Sgroi, Dennis C ^a   Ellisen, Leif W ^a   Winer, Eric P ^a   Garber, Judy E ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR E2F3; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ERBB2 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADJUVANT THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FRAMESHIFT MUTATION; GASTROINTESTINAL TOXICITY; GENE CLUSTER; GENE EXPRESSION; GERM LINE; HISTOPATHOLOGY; HUMAN; HYPERKALEMIA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONSENSE MUTATION; PHYSICIAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN METHYLATION; SCORING SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; TINNITUS; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CHEMISTRY; DNA METHYLATION; DNA MICROARRAY; GENETICS; MIDDLE AGED; MUTATION; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; GENES, BRCA1; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 77949908546     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.4725     Document Type: Article

References (49)

1. Liedtke C, Mazouni C, Hess KR, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281, 2008
2. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
3. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329-2334, 2007 (Pubitemid 46698581)
4. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005 (Pubitemid 41170290)
5. Foulkes WD, Stefansson IM, Chappuis PO, et al: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485, 2003 (Pubitemid 37279334)
6. Wang ZC, Lin M, Wei LJ, et al: Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 64:64-71, 2004 (Pubitemid 38114083)
7. Eisinger F, Jacquemier J, Charpin C, et al: Mutations at BRCA1: The medullary breast carcinoma revisited. Cancer Res 58:1588-1592, 1998 (Pubitemid 28215075)
8. Marcus JN, Watson P, Page DL, et al: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697-709, 1996 (Pubitemid 26055395)
9. Karp SE, Tonin PN, Begin LR, et al: Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80:435-441, 1997 (Pubitemid 27323413)
10. Verhoog LC, Brekelmans CT, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316-321, 1998 (Pubitemid 28052696)
11. Silver DP: HIN-1 and the nosology of breast cancer. Cancer Biol Ther 2:564-565, 2003
12. Nielsen TO, Hsu FD, Jensen K, et al: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374, 2004 (Pubitemid 39100473)
13. Lakhani SR, Reis-Filho JS, Fulford L, et al: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175-5180, 2005 (Pubitemid 41003703)
14. Feki A, Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 52:103-116, 2004 (Pubitemid 39419493)
15. Richardson AL, Wang ZC, De Nicolo A, et al: X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9:121-132, 2006 (Pubitemid 43202662)
16. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
17. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003 (Pubitemid 36842560)
18. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4:814-819, 2004
19. Scully R, Ganesan S, Vlasakova K, et al: Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 4:1093-1099, 1999 (Pubitemid 30054915)
20. Tassone P, Tagliaferri P, Perricelli A, et al: BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285-1291, 2003 (Pubitemid 36606348)
21. Rottenberg S, Nygren AO, Pajic M, et al: Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 104:12117-12122, 2007 (Pubitemid 47185639)
22. Ogston KN, Miller ID, Payne S, et al: A new histological grading system to assess response of breast cancers to primary chemotherapy: Prognostic significance and survival. Breast (Edinburgh, Scotland) 12:320-327, 2003
23. Kreike B, van Kouwenhove M, Horlings H, et al: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65, 2007
24. Turner NC, Reis-Filho JS, Russell AM, et al: BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26:2126-2132, 2007 (Pubitemid 46514749)
25. DeYoung MP, Johannessen CM, Leong CO, et al: Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma. Cancer Res 66:9362-9368, 2006 (Pubitemid 44623630)
26. Leong CO, Vidnovic N, DeYoung MP, et al: The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117:1370-1380, 2007 (Pubitemid 46718425)
27. Rocco JW, Leong CO, Kuperwasser N, et al: p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9:45-56, 2006 (Pubitemid 43069510)
28. Bild AH, Yao G, Chang JT, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439:353-357, 2006 (Pubitemid 43128862)
29. Whitfield ML, Sherlock G, Saldanha AJ, et al: Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000, 2002
30. Carter SL, Eklund AC, Kohane IS, et al: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38:1043-1048, 2006 (Pubitemid 44325930)
31. Chang HY, Sneddon JB, Alizadeh AA, et al: Gene expression signature of fibroblast serum response predicts human cancer progression: Similarities between tumors and wounds. PLoS Biol 2:E7, 2004
32. Teschendorff AE, Caldas C: A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 10:R73, 2008
33. Byrski T, Huzarski T, Dent R, et al: Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat, 115:359-363, 2009
34. Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506, 2007 (Pubitemid 47572635)
35. Hess KR, Anderson K, Symmans WF, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244, 2006 (Pubitemid 46630780)
36. Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13:7413-7420, 2007
37. Lowe SW, Ruley HE, Jacks T, et al: p53- dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993 (Pubitemid 23289454)
38. Di Leo A, Tanner M, Desmedt C, et al: p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol 18:997-1003, 2007 (Pubitemid 47050490)
39. Aas T, Børresen AL, Geisler S, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996 (Pubitemid 26225099)
40. Bertheau P, Turpin E, Rickman DS, et al: Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:e90, 2007
41. Tordai A, Wang J, Andre F, et al: Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10:R37, 2008
42. Holstege H, Joosse SA, van Oostrom CT, et al: High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69:3625-3633, 2009
43. Rocca A, Viale G, Gelber RD, et al: Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: Correlation with p63 expression. Cancer Chemother Pharmacol 61:965-971, 2008 (Pubitemid 351423123)
44. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991, 2006 (Pubitemid 44343542)
45. Ivanov O, Chen F, Wiley EL, et al: alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 111:411-417, 2008
46. Gauthier ML, Berman HK, Miller C, et al: Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell 12:479-491, 2007 (Pubitemid 350046408)
47. Herschkowitz JI, He X, Fan C, et al: The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10:R75, 2008
48. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001 (Pubitemid 32878711)
49. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3:1101-1108, 2008 (Pubitemid 351818697)